» Articles » PMID: 38653887

Impact of Probiotics on Gastrointestinal Function and Metabolic Status After Roux-en-Y Gastric Bypass: A Double-Blind, Randomized Trial

Overview
Journal Obes Surg
Date 2024 Apr 23
PMID 38653887
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Postoperative changes in gut microbiota may occur in patients undergoing Roux-en-Y gastric bypass surgery. In this study, we evaluate the impact of administering probiotic tablets on the gastrointestinal function and metabolic status of these patients.

Materials And Methods: This double-blinded randomized clinical trial was conducted from 2021 to 2022 on 135 Roux-en-Y surgery candidates. The intervention group underwent the surgical procedure and started receiving probiotic supplements (Familact Co.) 1 week after surgery; the control group received a placebo. The laboratory and anthropometric data were measured and analyzed before and 3 and 6 months after the intervention. GIQLI questionnaire was also used at the beginning and 6 months after the intervention to evaluate GI symptoms.

Results: We observed significantly reduced BMI in both groups after surgeries (P < 0.001). The levels of FBS and HbA1C were significantly lower in the probiotic group compared to the placebo in 3 months (P = 0.02 and P = 0.001, respectively) and 6 months (P < 0.001 for both) after the intervention. The levels of vitamin B12 increased significantly in the probiotic group (P < 0.001), and the values were substantially higher than the placebo group in 3 and 6 months (P < 0.001), respectively. Analysis of the GIQLI questionnaire before and 6 months after interventions also revealed significant improvement in the GIQLI score in both groups (P < 0.001 for probiotics and P = 0.03 for placebo).

Conclusion: Probiotic supplement administration following RYGB improves patients' vitamin and metabolic profile, as well as GI function, although it cannot significantly affect weight loss.

Citing Articles

Use of Probiotics and Synbiotics in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) and Other Gastrointestinal Symptoms After Metabolic Bariatric Surgery: a Systematic Review and Meta-Analysis.

Wagner N, Fernandes R, Teixeira Frota Reichmann M, Lopes M, Welc L, Campos A Obes Surg. 2024; 35(1):312-321.

PMID: 39607556 DOI: 10.1007/s11695-024-07599-2.


Initial Study on the Impact of Probiotics on Postoperative Gastrointestinal Symptoms and Gut Microbiota after Sleeve Gastrectomy: A Placebo-Controlled Study.

Dowgiallo-Gornowicz N, Mysiorska D, Sosnowska-Turek E, Botulinska A, Lech P Nutrients. 2024; 16(20).

PMID: 39458493 PMC: 11510060. DOI: 10.3390/nu16203498.


[Research progress of probiotics regulating intestinal micro-ecological environment in obese patients after bariatric surgery].

Zhang X, Wu M, Wang J, Chen J, Yu W, Pan H Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(5):659-666.

PMID: 39289777 PMC: 11528145. DOI: 10.3724/zdxbyxb-2024-0060.


Preoperative Multistrain Probiotic Supplementation Does Not Affect Body Weight Changes or Cardiometabolic Risk Factors in Bariatrics: Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Potrykus M, Czaja-Stolc S, Stankiewicz M, Szymanski M, Loniewski I, Kaska L Nutrients. 2024; 16(13).

PMID: 38999802 PMC: 11243469. DOI: 10.3390/nu16132055.

References
1.
Chooi Y, Ding C, Magkos F . The epidemiology of obesity. Metabolism. 2018; 92:6-10. DOI: 10.1016/j.metabol.2018.09.005. View

2.
Bray G, Fruhbeck G, Ryan D, Wilding J . Management of obesity. Lancet. 2016; 387(10031):1947-56. DOI: 10.1016/S0140-6736(16)00271-3. View

3.
Arterburn D, Telem D, Kushner R, Courcoulas A . Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020; 324(9):879-887. DOI: 10.1001/jama.2020.12567. View

4.
Lupoli R, Lembo E, Saldalamacchia G, Avola C, Angrisani L, Capaldo B . Bariatric surgery and long-term nutritional issues. World J Diabetes. 2017; 8(11):464-474. PMC: 5700383. DOI: 10.4239/wjd.v8.i11.464. View

5.
Pucci A, Batterham R . Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different. J Endocrinol Invest. 2018; 42(2):117-128. PMC: 6394763. DOI: 10.1007/s40618-018-0892-2. View